Pfizer to depart GSK's ViiV as Shionogi doubles its stake

FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update

FierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown

BioPharma DiveInnovation alone is no longer enough in biopharma

BioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalability

Roche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.com

FierceBiotechCould engaging the immune system improve AML outcomes?

FierceBiotechWhy AI is changing clinical development

FierceBiotechManaging complexity across biopharma modalities

eLifeA macroevolution-inspired approach to reveal novel antibiotic resistance mechanisms

eLifeA comprehensive mechanosensory connectome reveals a somatotopically organized neural circuit architecture controlling stimulus-aimed grooming of the <i>Drosophila</i> head

NINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBox

Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects